Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study

Abstract Antidepressant medications are commonly used to treat depression, but only about 30% of patients reach remission with any single first-step antidepressant. If the first-step treatment fails, response and remission rates at subsequent steps are even more limited. The literature on biomarkers...

Full description

Saved in:
Bibliographic Details
Published in:Contemporary clinical trials communications 2017-06, Vol.6 (C), p.22-30
Main Authors: Petkova, Eva, Ogden, R. Todd, Tarpey, Thaddeus, Ciarleglio, Adam, Jiang, Bei, Su, Zhe, Carmody, Thomas, Adams, Philip, Kraemer, Helena C, Grannemann, Bruce D, Oquendo, Maria A, Parsey, Ramin, Weissman, Myrna, McGrath, Patrick J, Fava, Maurizio, Trivedi, Madhukar H
Format: Article
Language:English
Subjects:
Combining biomarkers
Differential treatment response index
Moderator
Optimizing treatment decisions
Other
Precision medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Antidepressant medications are commonly used to treat depression, but only about 30% of patients reach remission with any single first-step antidepressant. If the first-step treatment fails, response and remission rates at subsequent steps are even more limited. The literature on biomarkers for treatment response is largely based on secondary analyses of studies designed to answer primary questions of efficacy, rather than on a planned systematic evaluation of biomarkers for treatment decision. The lack of evidence-based knowledge to guide treatment decisions for patients with depression has lead to the recognition that specially designed studies with the primary objective being to discover biosignatures for optimizing treatment decisions are necessary. Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) is one such discovery study. Stage 1 of EMBARC is a randomized placebo controlled clinical trial of 8 week duration. A wide array of patient characteristics is collected at baseline, including assessments of brain structure, function and connectivity along with electrophysiological, biological, behavioral and clinical features. This paper reports on the data analytic strategy for discovering biosignatures for treatment response based on Stage 1 of EMBARC.
ISSN:2451-8654
2451-8654
DOI:10.1016/j.conctc.2017.02.007